The expression of EPB41L3 was greatly reduced in many kinds of tumors, including non-small cell lung cancer [28], meningiomas [32], breast cancer [33], [34], renal clear cell carcinoma [35], and ovarian cancer [36]. Here, EPB41L3 is linked to clear cell renal carcinoma.